[Surgical aspects of acute sigmoiditis in amebiasis].

A. Carayon,C. Tournier-Lasserve

Abstract:

What problem does this paper attempt to address?

A High Frequency of CD8+CD28- T-suppressor Cells Contributes to Maintaining Stable Graft Function and Reducing Immunosuppressant Dosage after Liver Transplantation

Lei Geng,Jingfeng Liu,Junjie Huang,Bingyi Lin,Songfeng Yu,Tian Shen,Zhuoyi Wang,Zhe Yang,Lin Zhou,Shuseng Zheng

DOI: https://doi.org/10.7150/ijms.24042

2018-01-01

International Journal of Medical Sciences

Abstract:CD8+CD28-T cells (CD8Ts) exert immunosuppressive effects in various autoimmune diseases. The current study was designed to investigate the role of defects in CD8Ts in liver transplantation (LT). The proportion of CD8Ts in peripheral blood was determined by flow cytometry. The mean proportion of CD8Ts was 23.39% in recipients with stable graft function and 16.64% in those with graft dysfunction following LT compared with 19.86% in the healthy cohort. After receiving enhanced immunosuppressive therapy, patients in the rejection group who achieved recovery of graft function showed an increase in the proportion of CD8Ts (from 17.39% to 25.55%), but those in the group with refractory graft dysfunction showed no significant change (12.49% to 10.30%). Furthermore, in the first year after LT, recipients longer removed in time from the LT date exhibited a higher proportion of CD8Ts. Patients benefited most from tacrolimus concentrations of 5-10 ng/ml in the first year after LT and 0-5 ng/ml thereafter. Moreover, the change in the proportion of CD8Ts (ΔCD8Ts) was significantly higher in recipients with stable graft function than in those with graft dysfunction. These results suggest that a high frequency of CD8Ts prevents rejection and contributes to reduce immunosuppressant dosage and even induces tolerance.
Comparative risk assessment of residential radon exposures in two radon-prone areas, Stei (Romania) and Torrelodones (Spain).

C. Sainz,A. Dinu,T. Dicu,K. Szacsvai,C. Cosma,L. Quindós

DOI: https://doi.org/10.1016/j.scitotenv.2009.04.033

2009-07-15

Abstract:
Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies

Saifu Yin,Turun Song,Xingxing Li,Hanyue Xu,Xueling Zhang,Yamei Jiang,Tao Lin

DOI: https://doi.org/10.2174/1381612825666190717101941

Abstract:Background: Maintaining the exposure of tacrolimus (Tac) after kidney transplantation (KT) must be necessary to prevent acute rejection (AR) and improve graft survival，but there is still no clear consensus on the optimal Tac target blood concentration and concentration-effect relationship is poorly defined. Methods: We conducted a dose-response meta-analysis to quantitatively assess the association between Tac blood concentration and (AR) or adverse effects after KT. A comprehensive search of PubMed, Embase and Cochrane library databases was conducted to find eligible studies up to 10th September 2018. Unpublished data from patients receiving KT in West China Hospital (Sichuan University, China) were also collected. Both twostage dose-response and one-stage dose-response meta-analysis models were used to improve the statistical power. Results: A total of 4967 individuals from 10 original studies and 1453 individuals from West China Hospital were eligible for the ultimate analysis. In the two-stage dose-response meta-analysis model, we observed a significant non-linear relationship between Tac blood concentration and AR (P < 0.001) with moderate heterogeneity (I2 = 46.0%, P = 0.08). Tac blood concentration at 8ng/ml was associated with the lowest risk of AR (RR: 0.26, 95%CI: 0.13 - 0.54) by reference to 2ng/ml. Tac concentration at 7.0 - 11.0 ng/ml reduced the risk of AR by at least 70%, 5-14 ng/ml by at least 60%, and 4.5 - 14 ng/ml at least 50%. In the one-stage dose-response model, we also found a strong non-linear relationship between Tac and AR (P < 0.001) with moderate heterogeneity (I2 = 41.2%, P = 0.10). Tac concentration of 7.5 ng/ml was associated with the lowest risk of AR (RR: 0.35, 95%CI: 0.16 - 0.77). The blood concentration at 5.5 - 9.5 ng/ml was associated with the reduced AR by at least 60% and 4.5 - 10.5 ng/ml by at least 50% by reference to 2 ng/ml. Conclusion: Maintaining Tac blood concentration at 5 - 9.5 ng/ml within the first year may prevent AR most effectively.
Influence of Tacrolimus Intrapatient Variability on Allograft Rejection Frequency and Survival Following Liver Transplantation

Maria Eduarda Soares,Gabriela Costa,Laura Guerra,Maria Clara Morais,Nayana Vaz,Liana Codes,Paulo Lisboa Bittencourt

DOI: https://doi.org/10.1097/ftd.0000000000001192

2024-03-29

Therapeutic Drug Monitoring

Abstract:Background: Tacrolimus is the primary calcineurin inhibitor used in immunosuppressive regimens to prevent allograft rejection (AR) after organ transplantation. Recent studies have linked intrapatient variability (IPV) of tacrolimus with AR occurrence and reduced survival, especially in kidney transplant recipients. However, limited data are available on the impact of tacrolimus IPV on adverse outcomes after liver transplantation (LT). Aims: The aim of this study was to assess the association between tacrolimus IPV using various methodologies with acute AR and long-term patient survival after LT. Methods: All patients who underwent LT from January 2010 to July 2021 were retrospectively evaluated. Tacrolimus IPV was calculated for each patient using the mean and SD, mean absolute deviation (MAD), coefficient of variation (CV), and time in therapeutic range (TTR). These measures were then compared with AR within the first 24 months after LT and to long-term survival. Results: Out of 234 patients, 32 (13.7%) developed AR and 183 (78.2%) survived, with a mean follow-up of 101 ± 43 months. Tacrolimus IPV, assessed by mean, SD, MAD, and CV, was 8.3 ± 2.1, 2.7 ± 1.3, 32.0% ± 11.7%, and 39.4% ± 15.4%, respectively. There was no statistically significant correlation between Tacrolimus IPV and AR or survival post-LT. Conclusions: In a large cohort of patients from diverse racial backgrounds, tacrolimus IPV was not associated with clinically relevant outcomes such as AR and survival after LT.

pharmacology & pharmacy,medical laboratory technology,toxicology
Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

季曙明,陈江华,谭建明,张小东,朱同玉,陈立中,刘志红

DOI: https://doi.org/10.3969/j.issn.2095-4344.2013.05.003

2013-01-01

Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.
Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

史宪杰,董家鸿,纪文斌,段伟东,冷建军,王宏光,赵新,黄志强

DOI: https://doi.org/10.3969/j.issn.1672-8157.2008.02.002

2008-01-01

Abstract:Objective:To observe the clinic therapeutic effects of tacrolimus(FK506) in the recipients who had undergone liver transplantation.Methods:The clinical data of 69 recipients of allogeneic liver transplantation followed by tacrolimus based immunotherapeutic scheme were retrospectively analyzed in our hospital.After liver transplantation, all the recipients received the trilogy-drug immunosuppressive protocol, including tacrolimus(FK506) as the basic drug, mycophenolat-mofetil(MMF), and prednisone.Results:Acute rejection occurred in 8 of 69 cases(11.6%).After adjusting drug dose, acute rejection was reversed.The main side-effects of tacrolimus were spirit and nervous system confusion (20.3%), hypertension(11.6%), hyperglycemia(20.3%), liver and renal dysfunction(8.7%).Conclusion:Tacrolimus is a safe and potent immunosuppressive medicine, the dosage of FK506 should be adjusted according to trough level within the therapeutic window and individualized.
Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

JI Shu-ming,WEN Ji-Qiu,CHENG Dong-rui,WU Di,XIE Ke-nan,SUN Qi-quan,CHEN Jin-song,LIU Zhi-hong

DOI: https://doi.org/10.3969/j.issn.1674-7445.2012.02.009

2012-01-01

Abstract:Objective To evaluate the effect and safety of modest tacrolimus(FK506) reduction by programming renal biospies.Methods A prospective,randomized,open study was designed and forty-eight recipients undergoing firstly cadaveric renal transplantation were divided randomly into two groups: low dose tacrolimus group(Lo-FK506 group,n=24) and standard dose tacrolimus group(St-FK506 group,n=24).The recipients in both groups were treated with triple immunosuppression regimen including mycophenolate mofetil(MMF),FK506 and adrenal cortex hormone.The FK506 blood trough concentration of St-FK506 group was maintained at 10-12 ng/ml in the first three months after study entry,and then at 8-10 ng/ml after three months.The FK506 blood trough concentration of Lo-FK506 group was maintained at 8-10 ng/ml in the first two months after study entry,3-7 ng/ml in third month,3-5 ng/ml after 3 months.All patients were followed up for one year.The FK506 blood trough concentration,renal function[serum creatinine(Scr),endogenous creatinine clearance rate(Ccr)],fasting blood glucose,glycosylated hemoglobin,seralbumin and blood fat were examined and recorded regularly.At the same time,acute rejection(AR) occurrence,pathological damage index score and chronic allograft damage index(CADI)of recipients were evaluated by using renal graft biopsy(FNA) at month 3 and 12 post-transplantation.The 1-year survival rate of patients /grafts and the incidence of adverse event were observed.Results One year follow-up post-transplantation,FK506 blood trough concentration in the Lo-FK506 group was lower compared with St-FK506 group(P<0.01),but most of the patients reached the target level.The level of Ccr in Lo-FK506 group was higher than that of St-FK506 group[(83±14) ml / min vs(62 ±16) ml/min,P<0.05].The level of glucose was lower in Lo-FK506 group than that of St-FK506 group(P<0.05).According to the results of programming renal biopsies,interstitial fibrosis,tubular atrophy and glomerulosclerosis score were also lower in Lo-FK506 group(all in P<0.05).The incidence,severity of AR as well as 1-year survival rates of patient /graft was similar in both groups(P>0.05).The incidence of pulmonary infection and de novo diabetes one year posttransplant was significantly lower in Lo-FK506 group compared with St-FK506 group(P<0.05 and P<0.01 respectively).Conclusion It is reliable and helpful to evaluate the efficacy of modest tacrolimus reduction by programming renal biopsies and to find the chronic pathological changes of transplanted grafts.Modest reduction of the FK506 blood trough concentration in the early stage after transplantation is good for kidney grafts and recipients without increasing the risk of rejection.
Individualized immunosuppressive regimens for long-term surviving liver transplant recipients with chronic renal dysfunction

LI Rui-dong,DONG Jia-yong,TENG Fei,FU Zhi-ren,DING Guo-shan,WANG Zheng-xin

DOI: https://doi.org/10.3969/j.issn.1674-7445.2012.02.002

2012-01-01

Abstract:Objective To evaluate the effect of individualized immunosuppression regimens on chronic renal dysfunction in long-term surviving liver transplant recipients.Methods Thirty-two recipients over 18 years old were entered into the study,who underwent liver transplantation over 2 years.These recipients with normal liver function but impaired renal function,received tacrolimus(FK506) based immunosuppression regimen before study entry.Immunosuppression regimens were tailored according to the immune function and white blood cell(WBC) count,by reducing the dose of FK506 and conversion to mycophenolate mofetil(MMF) or sirolimus based immunosuppression protocol.After adjustmment for at least 1 time per month,hepatic function,renal function,blood routine examination and assessment of immune function were measured.Results After individualized immunosuppression regimens treatment,these patients were followed up for(24.3±7.6) months.Glomerular filtration rate was significantly elevated after treatment(all in P<0.01),which was most significant at 1 month after regimen adjustment.No rejection occurred during follow-up.Conclusions Indivi-dualized FK506-sparing immunosuppression regimens guided according to the immune function and WBC count can ameliorate renal dysfunction in long-term surviving liver transplant patients,but not increase the risk of rejection.
Lower Tacrolimus Trough Levels in the Late Period after Living Donor Liver Transplantation Contribute to Improvements in Long-Term Clinical Outcomes.

Lei Geng,Li-Dong Wang,Jun-Jie Huang,Tian Shen,Zhuo-Yi Wang,Bing-Yi Lin,Yu-Fu Ye,Shu-Sen Zheng

DOI: https://doi.org/10.1016/j.hbpd.2018.05.001

2018-01-01

Abstract:BACKGROUND:Previous studies have emphasized the need to reduce tacrolimus (TAC) trough levels in the early post-liver transplantation (LT) period. However, whether late-period TAC trough levels influence the long-term outcomes of liver recipients is not clear. METHODS:We enrolled 155 adult liver recipients survived more than 3 years after living donor liver transplantation because of non-malignant liver diseases. The maintenance immunosuppressive regimens were TAC monotherapy and combined therapy with mycophenolate mofetil. Patients were divided into three groups according to their late-period TAC trough levels: < 3 ng/mL group, 3-5 ng/mL group, and >5 ng/mL group. The complications and adverse effects of TAC were analyzed. RESULTS:Each group showed similar rejection, graft loss and mortality. Patients achieved the < 5 ng/mL state in less than 4 years had fewer new-onset diabetes, hyperlipidemia, de novo malignancies, and hepatitis B virus recurrence; the complications of renal dysfunction and hypertension rates were the same among these 3 groups. CONCLUSIONS:Collectively, our findings indicated that lower TAC trough levels in the late period of liver transplantation are safe, improve the long-term outcomes.
Immunosuppression protocols for emerging oncological indications in liver transplantation: A systematic review and pooled analysis

Roberta Angelico,Eliano Bonaccorsi Riani,Eleonora De Martin,Alessandro Parente,Maxime Foguenne,Bruno Sensi,Manuel L Rodríguez-Perálvarez,Liver Transplant Immunology Special Interest Group of the International Liver Transplant Society (ILTS)

DOI: https://doi.org/10.1097/LVT.0000000000000499

2024-10-01

Abstract:The evolving field of liver transplant (LT) oncology calls for tailored immunosuppression protocols to minimize the risk of tumor recurrence. We systematically reviewed the available evidence from inception to May 2023 regarding immunosuppression protocols used in patients undergoing LT for cholangiocarcinoma, neuroendocrine tumors (NET), hepatic-endothelial hemangioendothelioma, and colorectal liver metastases (CRLM) to identify common practices and to evaluate their association with oncological outcomes. Studies not involving humans, case reports, and short case series (ie, n < 10) were excluded. Among 3374 screened references, we included 117 studies involving 6797 patients distributed as follows: cholangiocarcinoma (58.1%), NETs (18.8%), hepatic-endothelial hemangioendothelioma (7.7%), CRLM (6.8%), mixed neoplasms (6.8%), or others (1.7%). Only 41% of the studies disclosed details of the immunosuppression protocol, and 20.8% of studies provided drug trough concentrations during follow-up. The immunosuppression protocols described were heterogeneous and broadly mirrored routine practices for nontumoral indications. The only exception was CRLM, where tacrolimus minimization-or even withdrawal-in combination with inhibitors of the mammalian target of rapamycin (mTORi) were consistently reported. None of the studies evaluated the relationship between the immunosuppression protocol and oncological outcomes. In conclusion, based on low-quality and indirect scientific evidence, patients with tumoral indications for LT should receive the lowest tacrolimus level tolerated under close surveillance. The combination with mTORi titrated to achieve the top therapeutic range of trough concentrations could allow complete tacrolimus withdrawal. This approach may be particularly useful in patients with cholangiocarcinoma and CRLM, in whom tumor recurrence is the main cause of death. We propose a tool for reporting immunosuppression protocols, which could be implemented in future transplant oncology studies.
EFFECTS OF IMMUNOSUPPRESSION AND ADJUVANT IMMUNE-TARGETED DRUGS IN PREVENTING HCC RECURRENCE AFTER LIVER TRANSPLANTATION

Hao Xing,Jianhua Li

DOI: https://doi.org/10.1097/01.tp.0000701928.85687.60

2020-01-01

Transplantation

Abstract:Liver Transplant Centre, Department of General Surgery, Huashan Hospital, Fudan University. Introduction: Hepatocellular carcinoma (HCC) is an increasingly common indication for liver transplantation (LT), while post-transplant HCC recurrence is the main problem affecting progonosis of recipients. From 2014 to 2019, HCC was the indication for 45% of liver transplant registrants in our center, as the most common reason for LT. Post-transplantation preventive measures including the immunosuppression regimen like sirolimus, and immunotherapies like sorafenib and lenvatinib. In this study, we aimed to explore the effects of sirolimus (SRL)/tacrolimus (TAC) and sorafenib/lenvatinib in preventing recurrence. Materials and Methods: This retrospective study including 207 recipients of liver transplants for hepatocellular carcinoma in Huashan hospitals affiliated to Fudan university. All recipients were followed up until December 2019 or until recurrence. The inclusion criteria: 1) histologically proven to be HCC; 2) without major vascular invasion. The exclusion criteria: 1) concurrent malignancy; 2) died within 3 months; 3) other malignancies. The baseline organ recipients’ demographic characteristics including age, sex, and transplant outcomes including cancer-related mortality. For groups, we constructed Kaplan-Meier curves to estimate overall survival proportions and cumulative incidence curves. All recipients received tacrolimus in their initial immunosuppressant regimen, and part of those received sirolimus in the long term regimen.Results and Discussion: Between 2014 and 2019, 207 liver recipients remained in our study population with a follow-up starting 3 months after transplantation (maximum follow-up of 5 years). Among these recipients, 78 (37.7%) received SRL in their long-term immunosuppressant regimen, 71(34.3%) received lenvatinib and most of recipients are beyond Milan criteria. In total, there were 69 recurrences and 32 cancer-related deaths. HCC recurrence rates was similar in sirolimus users and non-users in the In-Milan criteria, while appeared lower in sirolimus users compared with tacrolimus users in the Out-Milan criteria group. All recipients were clsssifed into six groups (SRL+ lenvatinib, TAC+ lenvatinib, SRL+ sorafenib, TAC+ sorafenib, SRL only, TAC only). The results show that especially in Out-Milan group, patients were benefied from TAC combined with lenvatinib effectively. Targeted therapies combined with sirolimus may bring a better prognosis among patients who do not meet the Milan criteria. Partly because of the limited data, the best combination of immunosuppression regimen and immunotherapies for different risky groups needs further study to be verified.Conclusion: In conclusion, immunosuppression and immune-targeted durgs are feasible measures for preventing HCC recurrence of recipients for HCC-transplantation. Intervention like modulating dose of SRL/TAC and sorafenib/lenvatinib may help patients prevent recurrence and receive a better long-term prognosis. References: 1. Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2016; 22 (5): 627. 2. Verna EC, Patel YA, Aggarwal A, et al. Liver transplantation for hepatocellular carcinoma: Management after thetransplant. American journal of transplantation: official journal of the American Society ofTransplantation and the American Society of Transplant Surgeons 2020; 20 (2): 333. 3. Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-basedimmunosuppression following liver transplantation for hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2019; 49 (10): 1260. 4. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in livertransplantation for hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2013; 37 (4): 411. 5. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England) 2018; 391 (10127): 1301.
Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation

Hiroyuki Kubo,Osamu Imataki,Tetsuya Fukumoto,Tomoya Ishida,Yukiko Hamasaki Kubo,Shunsuke Yoshida,Makiko Uemura,Haruyuki Fujita,Norimitsu Kadowaki

DOI: https://doi.org/10.1016/j.jcyt.2024.02.002

IF: 6.196

Cytotherapy

Abstract:Background aims: Tacrolimus (TAC) plus short-term methotrexate (stMTX) is used for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). TAC blood concentrations are frequently adjusted to enhance the graft-versus-leukemia/lymphoma effect or attenuate severe GVHD. Limited information is available on the clinical impact of these adjustments and the optimal time to perform them in order to achieve good clinical outcomes. Methods: We retrospectively analyzed 211 patients who underwent allo-HSCT at our institutes. Results: Higher TAC concentrations in week 3 correlated with a significantly higher cumulative incidence of relapse (CIR) (P = 0.03) and lower nonrelapse mortality (P = 0.04). The clinical impact of high TAC concentrations in week 3 on CIR was detected in the refined disease risk index: low/intermediate (P = 0.04) and high (P < 0.01), and conditioning regimens other than cyclophosphamide/total body irradiation and busulfan/cyclophosphamide (P = 0.07). Higher TAC concentrations in week 1 correlated with a lower grade 2-4 acute GVHD rate (P = 0.01). Higher TAC concentrations in weeks 2 and 3 correlated with slightly lower (P = 0.05) and significantly lower (P = 0.02) grade 3-4 acute GVHD rates, respectively. Higher TAC concentrations in weeks 1 and 3 were beneficial for severe acute GVHD in patients with a human leukocyte antigen-matched donor (P = 0.03 and P < 0.01, respectively), not treated with anti-thymocyte globulin (P = 0.02 and P = 0.02, respectively), and receiving three stMTX doses (P = 0.03 and P = 0.02, respectively). Conclusions: The clinical impact of TAC concentrations varied according to patient characteristics, including disease malignancy, conditioning regimens, donor sources, and GVHD prophylaxis. These results suggest that TAC management needs to be based on patient profiles.
[Lactate dehydrogenase subunit deficiencies].

T. Kanno

Seikagaku. The Journal of Japanese Biochemical Society

Abstract:
Population pharmacokinetics study of tacrolimus in liver transplant recipients: a comparison between patients with or without liver cancer before surgery

Haihong Bai,Juping Yun,Zihe Wang,Yingmin Ma,Wei Liu

DOI: https://doi.org/10.3389/fphar.2024.1449535

2024-08-23

Abstract:Background and objective: The main challenge for immunosuppressive therapy using tacrolimus in liver transplantation is the considerable variability in its oral bioavailability and the narrow treatment range. Many population pharmacokinetic (PopPK) models have been established to precisely estimate the PK variability of tacrolimus in liver transplant recipients. However, it remains unclear whether there is a significant difference in the PK behavior of tacrolimus between patients with or without liver cancer before surgery. Therefore, we aimed to compare the differences of PK parameters and simulate exposures of tacrolimus between populations preoperatively diagnosed with liver cancer or not by PopPK modeling. Methods: In total, 802 blood concentrations of tacrolimus from 196 patients (118 liver cancer and 78 non-liver-cancer samples) were included in this study. Demographic data and clinical parameters were integrated to perform a PopPK analysis using the nonlinear mixed-effects modeling approach. Potential covariates were evaluated by using a stepwise method. Goodness-of-fit plot and bootstrap were performed to assess the model stability and predictive performance. Simulations were introduced to optimize dosing regimens of both the liver cancer and non-liver-cancer groups according to the guidance. Results: The PK of tacrolimus was best described by a one-compartment model with first-order absorption and linear elimination, with weight and direct bilirubin as the significant covariates. In the process of constructing the basic model, we tried to separately estimate the PK parameters in liver cancer and non-liver-cancer populations. The results showed that the PK parameters in the two populations were similar, and the individual variation in Ka in non-liver-cancer subjects was large. Hence, the final model did not distinguish between the two populations. Moreover, a minor increase of less than 10% was observed in the simulated exposure in the patients preoperatively diagnosed with liver cancer compared with that in non-liver-cancer groups. Conclusion: The established PopPK model was capable of optimizing tacrolimus dosing in whole populations who underwent liver transplantation. Although a minimal difference was found in tacrolimus exposure between the liver cancer and non-liver-cancer groups, more research is warranted to explore the differences between the two populations in the future, given the potential limitations of this study.
Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-center experience

Chase J Wehrle,Roma Raj,Marianna Maspero,Sangeeta Satish,Bijan Eghtesad,Alejandro Pita,Jaekeun Kim,Mazhar Khalil,Esteban Calderon,Danny Orabi,Bobby Zervos,Jamak Modaresi Esfeh,Maureen Whitsett Linganna,Teresa Diago-Uso,Masato Fujiki,Cristiano Quintini,Choon David Kwon,Charles Miller,Antonio Pinna,Federico Aucejo,Koji Hashimoto,Andrea Schlegel,Chase J. Wehrle

DOI: https://doi.org/10.1097/js9.0000000000001104

2024-01-22

International Journal of Surgery

Abstract:Background: Liver transplantation (LT) is a well-established treatment for hepatocellular carcinoma (HCC), but there are ongoing debates regarding outcomes and selection. This study examines the experience of LT for HCC at a high-volume center. Methods: A prospectively maintained database was used to identify HCC patients undergoing LT from 2000-2020 with > 3 years follow-up. Data was obtained from the center database and electronic medical records. The Metroticket 2.0 HCC-specific five-year survival scale was calculated for each patient. Kaplan-Meier and Cox-regression analyses were employed assessing survival between groups based on Metroticket score and individual donor and recipient risk factors. Results: 569 patients met criteria. Median follow-up was 96.2 months (8.12 y; IQR 59.9-147.8). Three-year recurrence-free (RFS) and overall survival (OS) were 88.6% (n=504) and 86.6% (n=493). Five-year RFS and OS were 78.9% (n=449) and 79.1% (n=450). Median Metroticket 2.0 score was 0.9 (IQR 0.9-0.95). Tumor size>3 cm ( P =0.012), increasing tumor number on imaging ( P =0.001) and explant pathology ( P <0.001) was associated with recurrence. Transplant within Milan ( P <0.001) or UCSF-criteria ( P <0.001) had lower recurrence rates. Increasing AFP-values were associated with more HCC-recurrence ( P <0.001) and reduced OS ( P =0.008). Chemoembolization was predictive of recurrence in the overall population ( P =0.043) and in those outside Milan criteria ( P =0.038). A receiver-operator curve using Metroticket 2.0 identified an optimal cut-off of projected survival > 87.5% for predicting recurrence. This cut-off was able to predict RFS ( P <0.001) in the total cohort and predict both, RFS ( P =0.007) and OS ( P =0.016) outside-Milan. Receipt of donation after brain death (DBD) grafts (55/478, 13%) or living-donor grafts (3/22, 13.6%) experienced better survival rates compared to donation after cardiac death (DCD) grafts (n=15/58, 25.6%, P =0.009). Donor age was associated with a higher HCC-recurrence ( P =0.006). Both total ischemia time (TIT)>6hours ( P =0.016) and increasing TIT correlated with higher HCC-recurrence ( P =0.027). The use of DCD-grafts for outside-Milan candidates was associated with increased recurrence ( P =0.039) and reduced survival ( P =0.033). Conclusion: This large two-center analysis confirms favorable outcomes after LT for HCC. Tumor size and number, pre-transplant AFP, and Milan criteria remain important recipient HCC-risk factors. A higher donor risk (i.e., donor age, DCD-grafts, ischemia time) was associated with poorer outcomes.

surgery
''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Jun-Jun Jia,Bin-Yi Lin,Jiang-Juan He,Lei Geng,Dhruba Kadel,Li Wang,Dong-Dong Yu,Tian Shen,Zhe Yang,Yu-Fu Ye,Lin Zhou,Shu-Sen Zheng

DOI: https://doi.org/10.3748/wjg.v20.i32.11363

IF: 5.374

2014-01-01

World Journal of Gastroenterology

Abstract:AIM:To investigate the effect of the ''minimizing tacrolimus'' strategy on long-term survival of patients after liver transplantation (LT). METHODS:We conducted a retrospective study of 319 patients who received LT between January 2009 and December 2011 at the First Affiliated Hospital of Zhejiang University School of Medicine. Following elimination of ineligible patients, 235 patients were included in the study. The relationship between early tacrolimus (TAC) exposure and survival period was analyzed by Kaplan Meier curves. Adverse effects related to TAC were evaluated by the χ(2) test. Routine monitoring of blood TAC concentration (TC) was performed using the PRO-Trac(TM) II Tacrolimus Elisa Kit (Diasorin, United States). RESULTS:Of 235 subjects enrolled in the study, 124 (52.8%) experienced adverse effects due to TAC. When evaluating mean TC, the survival time of patients with a mean TC < 5 ng/mL was significantly shorter than that in the other groups (911.3 ± 131.6 d vs 1381.1 ± 66.1 d, 911.3 ± 131.6 d vs 1327.3 ± 47.8 d, 911.3 ± 131.6 d vs 1343.2 ± 83.1 d, P < 0.05), while the survival times of patients with a mean TC of 5-7, 7-10 and 10-15 ng/mL were comparable. Adverse effects due to TAC in all four groups were not significantly different. When comparing the standard deviation (SD) of TC among the groups, the survival time of patients with a SD of 2-4 was significantly longer than that in the other groups (1388.8 ± 45.4 d vs 1029.6 ± 131.3 d, 1388.8 ± 45.4 d vs 1274.9 ± 57.0 d, P < 0.05), while in patients with a SD < 2 and SD > 4, the survival time was not statistically different. Adverse effects experienced in all three groups were not statistically different. In Cox regression analysis, male patients and those with a primary diagnosis of benign disease, mean TC > 5 ng/mL and TC SD 2-4 had better outcomes. CONCLUSION:The early ''minimizing tacrolimus'' strategy with a mean TC of 5-10 ng/mL and SD of 2-4 was beneficial in terms of long-term survival after LT.
Use of Nuclear Factor of Activated T Cell-Regulated Gene Expression for Monitoring Immunosuppression with Extended-Release Tacrolimus after Liver Transplantation—A Proof of Concept

Judith Kahn,Eva Maria Matzhold,Peter Schlenke,Peter Schemmer

DOI: https://doi.org/10.3390/pharmaceutics16101317

IF: 6.525

2024-10-12

Pharmaceutics

Abstract:Background: There is a narrow therapeutic window for immunosuppression using calcineurin inhibitors. Drug trough levels do not reflect immunosuppression and should be replaced by pharmacodynamic monitoring. This prospective cohort study was designed to evaluate the effect of an extended-release formulation of tacrolimus (LCP Tac) on the nuclear factor of activated T cell-regulated gene expression (NFAT-RGE). Methods: The expression of interleukin-2, interferon-γ, granulocyte-macrophage colony-stimulating factor, and three reference genes was measured. Samples from 23 patients at defined time points in the first year after liver transplantation were analyzed using a droplet digital polymerase chain reaction. Results: All samples were within the targeted trough levels of LCP Tac, and their LCP Tac peak levels and residual NFAT-RGE showed a strong inverse correlation (r = −0.8). Most importantly, there was an individual immunosuppressive response to the LCP Tac. The mean individual trough effect of LCP Tac on the three target genes when all time points were pooled was 33% (26–56%) in patients without infection and 81% (53–95%) in those with infection (p < 0.011). The mean individual peak effect was 48% (44–64%) in patients without infection and 91% (90–94%) in those with infection (p < 0.001). Conclusion: Thus, tailored immunosuppression based on residual NFAT-RGE could prevent infections associated with over-immunosuppression early after liver transplantation.

pharmacology & pharmacy
Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study

Laura Lladó,Ana González-Castillo,Joan Fabregat,Carme Baliellas,Emilio Ramos,Emma González-Vilatarsana,Juli Busquets,Xavier Xiol

DOI: https://doi.org/10.12659/AOT.912444

2019-01-18

Abstract:BACKGROUND Delaying initiation of tacrolimus after liver transplantation (LT) is a potential renal-sparing strategy. We assessed safety and efficacy of delayed initiation of prolonged-release tacrolimus (PR-T) in de novo LT. MATERIAL AND METHODS This was a single-center, single-arm, prospective, 12-month observational study of hepatitis C virus-negative orthotopic LT patients. Immunosuppression included PR-T (initially 0.1 or 0.2 mg/kg/day) initiated on Day 3 post LT, basiliximab (20 mg) on post-transplantation Day 0 and Day 4, and intraoperative corticosteroids (500 mg). Patients received maintenance corticosteroids and mycophenolate mofetil (MMF) according to center protocol. MMF dose was adjusted according to thrombocyte count. The primary endpoint was the estimated glomerular filtration rate (eGFR) measured using the Modification of Diet in Renal Disease 4-variable formula at 12 months. Secondary endpoints included biopsy-confirmed acute rejection (BCAR) and dialysis requirement. Adverse events were recorded. RESULTS Sixty-nine patients (mean age 55.0 years) were included. Most patients started MMF on Day 1 (60.9%) or Day 2 (10.1%), and PR-T on Day 3 (55.1%) or Day 4 (29.0%). Mean tacrolimus trough levels (ng/mL) were: Day 7, 9.5±6.3; Day 10, 9.4±5.4; Month 1, 8.0±3.1; Month 3, 7.8±3.7; Month 6, 8.0±4.1; and Month 12, 7.2±3.1. Mean 12-month eGFR was 77.2±24.5 mL/min/1.73 m2; 72.5% of patients had eGFR >60 mL/min/1.73 m² at 12 months; 89.9% had no eGFR measurements <40 mL/min/1.73 m² during the study. Renal insufficiency (any eGFR <60 mL/min/1.73 m²) was diagnosed in 27.5% of patients; one patient required dialysis. There were no BCAR episodes; the infection rate was 36.2%, and 3 patients died. Overall, 19 patients (27.5%) developed de novo diabetes mellitus, 18 patients (26.1%) had hypercholesterolemia, and 12 patients (17.4%) had hypertriglyceridemia. CONCLUSIONS Quadruple therapy with delayed administration of PR-T was well tolerated and efficacious, and was associated with acceptable renal function over 12 months.
Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation

Itziar Oteo,John C Lukas,Nerea Leal,Elena Suarez,Andres Valdivieso,Mikel Gastaca,Jorge Ortiz de Urbina,Rosario Calvo

DOI: https://doi.org/10.1007/s00228-011-0998-3

Abstract:Purpose: To explore the main factors that make it difficult to empirically monitor tacrolimus (TAC) in the early period post-liver transplantation (LTx), with a specific focus on those aspects related to patient idiosyncrasy and clinical status as well as to the pharmacokinetic (PK) assumptions on which drug individualization in clinical practice is based. Methods: Retrospective monitoring data from 75 de novo liver transplant patients treated with twice daily with TAC and followed for up to 15 days were analyzed. An extensive battery of laboratory measurements were available. Dose adjustment was performed empirically using trough levels (C(min)). The population was separated into two major background groups according to low or high values of aspartate aminotransferase (AST) (Group 1 and 2, respectively) based on AST measurements made during the first 4 days post-LTx. Each of these two major groups was then further subdivided into two subgroups based on elevated (Groups 1A, 2A) or reduced (Groups 1B, 2B) combined albumin (cut-off 2.5 g/dl) and hematocrit (cut-off 28%). Results: The C(min)/Dose ratio [inversely proportional to systemic clearance (CL)] had a variability [coefficient of variation (CV) >80%) that was incongruently higher for the ratio than for C(min) and Dose separately. This was attributed to most patients not being at steady state or physiologically stable in the early post-LTx period. Group 1 patients were more predictable than Group 2 patients, who were responsible for the variability in the ratio. C(min) was lower in the reduced ALB and HCT patient groups when AST conditions were similar (1A vs. 1B and 2A vs. 2B), likely due to increased TAC metabolic clearance (reduced C(min)/Dose). This situation existed for two periods: 0-15 days post-LTx and 4-15 days post-LTx observations. Group 2A patients were the main source of the paradoxical variability in C(min)/Dose (higher ratio of 2.7; CV = 100%), suggesting a lower clearance and difficulty in the recovery of stability. In contrast, Group 2B patients had the lower ratio (1.4; 47%) but required the highest number of dose adjustments as the variability was hard to identify clinically. Group 1A patients were the most predictable empirically. When observations from 15 new patients who entered the clinic in 2007 and 2008 were used for the analysis, the same sub-groups existed in the same proportions in both years. Conclusion: The difficulty in empirical dose adjustment of TAC is associated to the inevitable non-fulfillment of PK assumptions early post-LTx and also to the inherent complexity of the clinical condition, leading to increased uncertainty for the clinician regarding dose selection. Identifying these sub-categories provides a rational means of classifying patients akin to a phenotype. The complexity of the kinetics in LTx and TAC treatment does not invalidate C(min) as a biomarker, but a Bayes algorithm including a full PK structure and these covariates would be optimal.
Adequate cumulative exposure to tacrolimus and low tacrolimus variability decrease the incidence of biliary complications after liver transplantation

Bi Pan,Yuancheng Li,Xiaojun Wang,Yanjiao Ou,Gang Heng,Xingchao Liu,Di Jiang,Wei Liu,Yixian Huang,Feng Hu,Zeliang Xu,Zhiyu Chen,Leida Zhang,Chengcheng Zhang

DOI: https://doi.org/10.1016/j.intimp.2023.111461

IF: 5.714

2024-01-04

International Immunopharmacology

Abstract:Background Nonearly biliary complications (BCs) after liver transplantation (LT) are highly associated with immunological status. Tacrolimus is the main immunosuppressant. Whether and how tacrolimus bioavailability affects BCs is unclear. Methods LT recipients receiving tacrolimus-free immunosuppressants or developing BCs within 3 months after LT were excluded. Tacrolimus-related variables included trough concentration (C0), variability and cumulative exposure to tacrolimus (CET). Receiver operating characteristic (ROC) curves defined cutoff values of CET and variability. The values divided patients into adequate and low CET groups, also high and low-variability groups. Inverse probability of treatment weighting (IPTW) was used to reduce bias. Logistic regression identified risk factors. Kaplan–Meier curves were generated for survival comparison. Results 409 patients were enrolled, and 39 (9.5 %) suffered from BCs. The mean C0 values were 6.9 and 7.2 ng/mL in the BCs and BCs-free groups, respectively. CET within 3 postoperative months was 550.0 and 608.6 ng.day/mL, while the tacrolimus variability was 0.4 and 0.3, respectively. The cutoff values for CET within 3 months and variability predicting BCs were 660.5 and 0.54, respectively. Multivariable logistic regression revealed that low CET within 3 months (p = 0.005, p = 0.002) and high variability (p < 0.001, p < 0.001) were associated with BCs before and after IPTW. Appropriate CET and low variability were associated with better overall survival (p = 0.009 and 0.029). Subgroup analysis indicated that long cold ischemia time (CIT), high bilirubin and low CET had a higher relative risk and raised the incidence of BCs. Conclusions Adequate CET and low variability of tacrolimus ameliorated nonearly BCs incidence and improved survival.

pharmacology & pharmacy,immunology

[Surgical aspects of acute sigmoiditis in amebiasis].

A High Frequency of CD8+CD28- T-suppressor Cells Contributes to Maintaining Stable Graft Function and Reducing Immunosuppressant Dosage after Liver Transplantation

Comparative risk assessment of residential radon exposures in two radon-prone areas, Stei (Romania) and Torrelodones (Spain).

Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies

Influence of Tacrolimus Intrapatient Variability on Allograft Rejection Frequency and Survival Following Liver Transplantation

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

Individualized immunosuppressive regimens for long-term surviving liver transplant recipients with chronic renal dysfunction

Lower Tacrolimus Trough Levels in the Late Period after Living Donor Liver Transplantation Contribute to Improvements in Long-Term Clinical Outcomes.

Immunosuppression protocols for emerging oncological indications in liver transplantation: A systematic review and pooled analysis

EFFECTS OF IMMUNOSUPPRESSION AND ADJUVANT IMMUNE-TARGETED DRUGS IN PREVENTING HCC RECURRENCE AFTER LIVER TRANSPLANTATION

Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation

[Lactate dehydrogenase subunit deficiencies].

Population pharmacokinetics study of tacrolimus in liver transplant recipients: a comparison between patients with or without liver cancer before surgery

Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-center experience

''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Use of Nuclear Factor of Activated T Cell-Regulated Gene Expression for Monitoring Immunosuppression with Extended-Release Tacrolimus after Liver Transplantation—A Proof of Concept

Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study

Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation

Adequate cumulative exposure to tacrolimus and low tacrolimus variability decrease the incidence of biliary complications after liver transplantation